Semaglutide Appears To Double Risk Of Vision Loss For Those With Type 2 Diabetes

People with type 2 diabetes (T2D) who were using semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), were twice as likely to lose vision due to nonarteritic anterior ischemic optic neuropathy (NAION) than people with T2D who were not using semaglutide. Among people with T2D, across 1.9 million person years of observation from 2019 through 2023, the incidence of NAION was 0.114 cases per 1,000 person years. Among those exposed to semaglutide, the incidence of NAION was 0.228 per 1,000 person-years compared to 0.093 per 1,000 person-years among . . .